BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T041212
CREATED:20220720T112134Z
LAST-MODIFIED:20220720T112134Z
UID:34732-1669593600-1669939199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Summit 2022
DESCRIPTION:The past twelve months have culminated in an unprecedented level of excitement\, investment\, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy\, in the context of increased regulatory scrutiny and safety challenges\, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important. \nThis year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech\, pharma and academia to continue to develop resilient\, long-lasting and robust analytical tools to enhance the safety\, quality and efficacy of gene therapy products.   \nWhether you are focusing on specific characterization methods\, enhancing your genome sequencing\, advancing your understanding of full and partial particles\, or advancing your early-stage bioassays\, with 4 tracks\, 8 pre-conference workshops and a post-conference focus day\, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development\, giving you the chance to address and overcome challenges. \nIf you work in quality control\, quality assurance\, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments\, bridging between analytical methods with regards to QC/PD\, and enhancing in-process development support. \nWhether you’re working with AAV\, non-viral vectors or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/w2diiu
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-summit-2022/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T041212
CREATED:20220811T093237Z
LAST-MODIFIED:20220811T093237Z
UID:34895-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:4th Inflammasome Therapeutics Summit
DESCRIPTION:The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma\, biotechs\, and academic KOLs\, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs\, which are shaking up the immunology R&D landscape. \nAs the space eagerly awaits data readouts from proof-of-concept trials\, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on: \n\nDeciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system \nOvercoming limitations of preclinical models\, identifying clinically meaningful biomarkers of inflammasome inhibition\, and defining good clinical endpoints \nTaming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets \nDelving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful\n\nJoin 120+ fellow peers and industry heavyweights this Fall including NodThera\, Novartis\, Zyversa Therapeutics\, and more\, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/4th-inflammasome-therapeutics-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T041212
CREATED:20220811T093818Z
LAST-MODIFIED:20220815T091224Z
UID:34899-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:6th Obesity & NASH Drug Development Summit
DESCRIPTION:The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints\, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. \n \nWith mounting competition for the market in obesity and all eyes on the next wave of NASH candidates\, the 6th Obesity & NASH Drug Development Summit\, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization. \nJoin 150+ industry pioneers in Boston including pioneers Novo Nordisk\, Eli Lilly\, Boehringer Ingelheim\, Pfizer\, Inventiva\, Regeneron\, FDA\, AstraZeneca\, and more to advance your pipeline towards approved treatment. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/6th-obesity-nash-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T041212
CREATED:20220824T095329Z
LAST-MODIFIED:20220824T114844Z
UID:34996-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:3rd CRISPR 2.0 Summit
DESCRIPTION:Recognized with a Nobel Prize in 2020\, CRISPR has opened the floodgates for a new era of gene editing therapies\, promising to transform genetic disease treatments. With a well-established early field of genomics research\, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit\, including Cas nucleases\, base and prime editing technologies\, and innovative delivery platforms. \nThe 3rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy\, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic. \nAcross three days of content\, co-designed with 27+ industry thought leaders\, this streamlined one-track summit will unite 100+ key players in the CRISPR space\, from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to market for your CRISPR gene editing program. \nHere’s a snapshot of our 27+ thought leaders: \n\nKiran Musunuru\, Professor of Medicine\, Perelman School of Medicine\, University of Pennsylvania\nAmy Simon\, Chief Medical Officer\, Beam Therapeutics\nJane Grogan\, Chief Scientific Officer\, Graphite Bio\nLiron Walsh\, Head of Development; In Vivo Programs\, Intellia Therapeutics\nJeremy Duffield\, Chief Scientific Officer\, Prime Medicine\nEric B. Kmiec\, Executive Director & Chief Scientific Officer\, Christiana Care Gene Editing Institute\nRafi Emmanuel\, Senior Vice President – Research & Development\, Emendo Biotherapeutics\nJohn Murphy\, Chief Scientific Officer\, Arbor Biotechnologies\nInge Yung-Chih Cheng\, Principal Scientist\, Pfizer\nJoey Riepsaame\, Head of Genome Engineering\, University of Oxford\nRammohan Devulapally\, Principal Scientist\, GenEdit\n\nBe part of the community as we dive deep into: \n\nRefining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy\, with help from GenEdit and the latest research from the David Liu Lab.\nFrom bench to bedside: translating basic CRISPR research into a viable therapeutic product\, with Beam Therapeutics\nLeverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders\, with Prime Medicine and UC Irvine.\n\nAnd more! \nJoin this unmissable summit and network experts from the likes of Beam Therapeutics\, The David Liu Lab\, Pfizer\, GenEdit\, AZ\, GSK\, Caribou Biosciences\, Prime Medicine\, Intellia Therapeutics and many more. \nTo know more visit: https://ter.li/vumobp
URL:https://www.pharmajournalist.com/event/3rd-crispr-2-0-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260516T041212
CREATED:20220923T091314Z
LAST-MODIFIED:20220923T091314Z
UID:35230-1669852800-1670025599@www.pharmajournalist.com
SUMMARY:PAT & Real Time Quality Summit
DESCRIPTION:The time has come to remove the pharmaceutical industry’s reliance on archaic off-line testing and embrace the cost and speed-to-market savings of online control and real-time product quality. \nThe PAT market is projected to reach USD 4.96 Billion by 2027\, spurred on by the recent ICH Q14/ Q2 (R2) guidelines\, there has never been a more opportune moment to leverage regulator’s support of QbD\, real-time control\, and process intervention to achieve meaningful business impact in your organization\, through reduced downtime\, manufacturing footprint\, ease of scale-up and product consistency for approval. \nWhether you’re applying in small molecules\, biologics\, or ATMP\, bridge the gap in technology\, culture\, or regulatory experience that is the bottleneck to your organization saving an average 50% reduction in process cycle time and winning speed to market\, with the strategical implementation of smart process analytical technologies and quality by control (QbC). \nJoin a senior community of experts in process development\, manufacturing\, regulatory & quality to understand how to monitor critical quality attributes with reactive and predictive control systems and discover novel PAT technologies as the industry moves the needle toward realizing real-time release. \nTo know more visit: https://ter.li/080rbc
URL:https://www.pharmajournalist.com/event/pat-real-time-quality-summit/
LOCATION:Hilton San Diego Gaslamp Quarter\, 401 K Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T041212
CREATED:20220819T112000Z
LAST-MODIFIED:20220819T112000Z
UID:34927-1670198400-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders
DESCRIPTION:Delivering the Next Wave of Gene Therapies to the CNS \nWith systemic toxicity challenges plaguing the AAV field\, direct administration for CNS indications creates an ideal target for gene therapy. This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets. \nThe 4th Annual Gene Therapy for Neurological Disorders Summit will unite gene therapy developers with an industry-focused agenda across 4 days and 2 dedicated tracks of content to solve the preclinical\, translational and clinical challenges of targeting a wide range of neurodevelopmental and neurodegenerative disorders with both ‘first’ and ‘next’ generation gene therapies. \nJoin the expanding audience of gene therapy experts to: \n\nStreamline CNS drug delivery devices for improved brain biodistribution\nDiscover novel vectors for CNS specificity & tropism\nOptimize gene therapy strategy for pediatric & adult neurological disorders\n\nTo know more visit: https://ter.li/rluqrj
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders/
LOCATION:The Westin Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221208
DTSTAMP:20260516T041212
CREATED:20220919T115535Z
LAST-MODIFIED:20220919T115535Z
UID:35224-1670198400-1670457599@www.pharmajournalist.com
SUMMARY:4th Annual Cell Therapy Analytical Development Summit
DESCRIPTION:Cell Therapy Analytical Development Summit US is back for its fourth year\, taking place in Boston (December 5-7). Join 180+ colleagues from analytical development\, process development\, quality control and regulatory affairs\, to standardize analytical testing and take advantage of unrivalled content across: \n\n3-days\n6 deep-dive workshops\n2 tracks\n\nSeize an unmatched opportunity to delve into cell potency\, safety\, viability\, sterility and more across both autologous and allogeneic cell therapy products. \nPlease use this URL – https://ter.li/ghwxjk
URL:https://www.pharmajournalist.com/event/4th-annual-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T041212
CREATED:20220914T121744Z
LAST-MODIFIED:20220914T121744Z
UID:35170-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:5th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 5th Commercializing Clinically Validated Digital Therapeutics Summit\, designed with DTx companies\, pharma and clinicians\, will return this December to address the industry’s major challenges such as improving user experience\, clinical trial development\, and standing out in a crowded market through open discussion and case-study led presentations.   \nWhether you’re a veteran at commercializing clinically validated digital therapeutics\, looking for partnerships\, or a new entrant to the field\, you’ll leave this conference with practical lessons and essential connections needed to supercharge DTx commercial ambitions across 2022 and beyond. \nTo know more visit: https://ter.li/5e6hqd
URL:https://www.pharmajournalist.com/event/5th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T041212
CREATED:20221024T225543Z
LAST-MODIFIED:20221025T102843Z
UID:35606-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:The long-awaited 4th Annual Targeted Radiopharmaceuticals Summit Europe is returning in-person in Amsterdam on December 6-8\, 2022! \nAs the only devoted meeting for large pharma\, biotech and pioneering academics\, this meeting unites key stakeholders under the mutual and ambitious objective of advancing radioligand candidates to commercialisation through rigorous clinical rationale and reliable supply chain design. \nDownload the full Event Guide to learn what the 29+ expert speakers will present on\, including: \n\n\n\nMeeting the newest contenders to enter the field including Ariceum Therapeutics and TRIMT\nDiscovering new targeting systems that are opening avenues to treating more cancers with Tagworks and Ratio Therapeutics\nGetting the most up-to-date information on current radionuclide stocks and how the world’s leading isotope producers are increasing their production and variety of products with Duke University\nEnhancing your trial design to conduct the most rigorous trials with help from leading clinical stage companies with Oncoinvent\nThe ability to showcase your work and meet new people across dedicated sessions and have the meetings that will help you build vital collaborations\n\n\n\nAccess the official Event Guide here to see the complete agenda and speaker line up.
URL:https://www.pharmajournalist.com/event/4th-annual-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Leonardo Royal Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221208
DTSTAMP:20260516T041212
CREATED:20221110T115946Z
LAST-MODIFIED:20221110T115946Z
UID:35768-1670284800-1670457599@www.pharmajournalist.com
SUMMARY:2nd Next-Generation Food Allergy Drug Development Summit
DESCRIPTION:The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on\, but access to funding and large patient cohorts\, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. \nThe 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies\, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need. \nJoin us in-person for the first time in Boston as the food allergy community comes together to unravel the complex regulatory landscape\, identify and validate novel clinical biomarkers to aid patient selection and explore novel routes of administration to innovate long-lasting\, next-generation treatments. \nTo know more visit: https://bit.ly/3GlzzRp
URL:https://www.pharmajournalist.com/event/2nd-next-generation-food-allergy-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221207
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T041212
CREATED:20220727T082442Z
LAST-MODIFIED:20220727T082442Z
UID:34784-1670371200-1670543999@www.pharmajournalist.com
SUMMARY:3rd TIGIT Axis Therapies Summit
DESCRIPTION:In the context of a need to regroup and accelerate practice-changing cancer immunotherapies towards approval and to patients in need\, the 3rd TIGIT Axis Therapies Summit returns to reunite large pharma\, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor\, blood cancer and non-oncology setting. \nCovering deciphering the mechanistic intricacies underlying TIGIT axis signaling\, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines\, exploring novel drug designs in terms of Fc functionality and IgG type\, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design\, this is your comprehensive guide for addressing the unique challenges of TIGIT axis targeted drug development and powering up your pipelines. \nThis year’s sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups\, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs. \nFind out more here: https://ter.li/ir0syg
URL:https://www.pharmajournalist.com/event/3rd-tigit-axis-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260516T041212
CREATED:20220728T084521Z
LAST-MODIFIED:20220728T084521Z
UID:34801-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:5th Annual RNA-Targeted Drug Discovery Summit
DESCRIPTION:RNA-Targeted Drug Discovery Summit returns for its fifth year this December. Join the summit for deep dive into new and emerging topics such as: \n\nInduced Proximity as a new class of “targeted RNA degraders”\nNext-generation probing and screening technologies to accelerate HIT identification and validation\nBiophysical\, biochemical\, and cell-based assay development strategies to identify and optimize small molecules interacting with RNA\nIn vivo pharmacology\, safety\, and efficacy early considerations to accelerate the transition from discovery to pre-clinical and clinical development\n\nView the event program here: https://ter.li/7qs017 \nSecure your place here: https://ter.li/jlh128 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/5th-annual-rna-targeted-drug-discovery-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260516T041212
CREATED:20220822T112559Z
LAST-MODIFIED:20221018T100720Z
UID:34982-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:2nd Synthetic Biology-Based Therapies Summit
DESCRIPTION:Returning for a second year the Synthetic Biology-Based Therapies Summit is the leading industry-defining forum made exclusively for leaders in the synthetic and engineered biology space\, focusing on the technical challenges that lie ahead in the path towards commercialization. \nDownload the event guide to find out more \nLearn from industry trailblazers at Arsenal Biosciences\, bit.bio\, Moderna\, MIT\, Novome Bio\, Strand Therapeutics\, Synlogic and more\, to support your efforts in developing safe and effective synthetic biology-based therapeutics. \nJoin Global Innovators to: \n\nLearn from the academics that are driving the future of synthetic biology development with the National Institute of Standards & Technology and Massachusetts Institute of Technology\nLeverage novel control strategies for improved therapeutic efficacy and patient safety with Arsenal Biosciences\, bit.bio\, CHAIN Biotechnology and Strand Therapeutics\nEmploy synthetic biology techniques in the clinic\, hearing about a variety of therapeutic applications with Kite Pharma: A Gilead Company\, Novome Biotechnologies and Senti Biosciences\nApply computation\, artificial intelligence\, and machine learning to engineered and synthetic biology with Lawrence Berkley National Laboratory and Sanofi\nExplore the potential for engineered biology as a tool for drug discovery and development with LifeMine Therapeutics and Merck & Co.
URL:https://www.pharmajournalist.com/event/2nd-synthetic-biology-based-therapies-summit/
LOCATION:(exact venue TBC)\, Boston\, US.
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221215
DTSTAMP:20260516T041212
CREATED:20220909T103058Z
LAST-MODIFIED:20220909T103058Z
UID:35114-1670889600-1671062399@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit Europe 2022
DESCRIPTION:The Advanced Wound Care Summit EU is the first industry-led\, EU-focused\, forum on commercialising innovative wound care products. How will you comply with the EU MDR? What is the best strategy to ensure widespread clinical adoption and reimbursement? What can you do to engage with other wound care companies\, for collaboration or acquisition? Expect to hear from\, and network with\, wound care leaders\, across large wound care companies and SMEs. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges\, seizing growth opportunities\, and building innovation. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to secure your stake in the AWC market. \nTo know more visit: https://hubs.ly/Q01lR8NX0
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit-europe-2022/
LOCATION:TBC\, Berlin\, Germany
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221214
DTEND;VALUE=DATE:20221215
DTSTAMP:20260516T041212
CREATED:20221018T101336Z
LAST-MODIFIED:20221018T105122Z
UID:35527-1670976000-1671062399@www.pharmajournalist.com
SUMMARY:PURIFY – Chromatography Purification Conclave
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
URL:https://www.pharmajournalist.com/event/purify-chromatography-purification-conclave/
LOCATION:Taj Skyline\, Ahmedabad
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
END:VCALENDAR